Resolution Bioscience announced it had entered a companion diagnostic agreement with Mirati Therapeutics. Under the agreement, Resolution will leverage its ctDx liquid biopsy platform to identify patients who may benefit from Mirati’s investigation KRAS G12C inhibitor in the treatment of non-small cell lung cancer (NSCLC).
“We are excited to join forces with Mirati to address this large unmet medical need and to further drive adoption of our innovative liquid biopsy diagnostic tests,” said Mark Li, CEO of Resolution Bioscience in a press release. “Our mission is to provide critical, actionable information to improve care and clinical outcomes for cancer patients worldwide.”
Cancers stemming from RAS mutations account for nearly a quarter of all human cancers, with the KRAS mutation the most common, comprising 85% of the RAS family oncogenes. Mirati’s investigational drug candidate adagrasib (MRTX849) is an orally available small molecule that potently and selectively inhibits the G12C substitution mutation. The non-invasive assay from Resolution will be used to identify patients whose cancers are driven by this KRAS variant.
Resolution’s liquid biopsy assays feature the company’s patented cell-free DNA (cfDNA) analysis platform, which includes proprietary targeted capture next-generation sequencing (NGS) biochemistry and cloud-based bioinformatics. The liquid biopsy assays are designed to provide rapid and accurate tumor genotyping, all without an invasive tissue procedure.